首页> 外文OA文献 >Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation

【2h】

Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation

机译：吉非替尼对肺腺癌患者阳性外显子21或19 Del表皮生长因子受体突变的第一和二线治疗的比较

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Nishant Patel; Pingping Wu; Haijun Zhang;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation [J] . Nishant Patel, Pingping Wu, Haijun Zhang Cancer Management and Research . 2017,第1期

机译：吉非替尼作为一线和二线疗法治疗外显子21或19 del表皮生长因子受体阳性的晚期肺腺癌的比较
2. Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation? [J] . Amit Joshi, Vijay Patil, Vanita Noronha, Lung India . 2018,第1期

机译：吉非替尼在表皮生长因子受体激活突变阳性非小细胞肺癌中的功效：外显子19缺失与外显子21突变有区别吗？
3. Detection of epidermal growth factor receptor (EGFR) exon 19 E746-A750 deletion and EGFR exon 21 point mutations in lung adenocarcinoma by immunohistochemistry: a comparative study to EGFR exons 19 and 21 mutations analysis using PCR followed by high-resolution melting and pyrosequencing [J] . Chabot-Richards Devon, Buehler Karen, Vasef Mohammad A. Journal of Histotechnology: An Offical Publication of the National Society for Histotechnology . 2015,第2期

机译：免疫组织化学检测肺腺癌中表皮生长因子受体（EGFR）外显子19 E746-A750缺失和EGFR外显子21点突变：使用PCR结合高分辨率熔解和焦磷酸测序对EGFR外显子19和21突变进行比较研究
4. HER1 THERAPEUTIC CANCER VACCINE: AN ACTIVE IMMUNOTHERAPY TREATMENT FOR PATIENTS WITH TUMORS EXPRESSING THE RECEPTOR OF EPIDERMAL GROWTH FACTOR (EGF-R) [C] . Eduardo Suarez, Belinda Sanchez, Zaima Mazorra, Conference on vaccine technology VI . 2018

机译：HER1癌症治疗疫苗：一种针对表皮生长因子（EGF-R）受体的肿瘤的主动免疫疗法
5. The characteristics of the course of the disease in lung adenocarcinoma in relation to activating mutations of the gene for epidermal growth factor receptor. [D] . Stanic, Karmen. 2015

机译：与表皮生长因子受体基因激活突变有关的肺腺癌疾病病程特征。
6. Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation [O] . Nishant Patel, Pingping Wu, Haijun Zhang 2017

机译：吉非替尼作为一线和二线疗法治疗外显子21或19 del表皮生长因子受体阳性的晚期肺腺癌的比较
7. Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation? [O] . Amit Joshi, Vijay Patil, Vanita Noronha, 2018

机译：吉非替尼在表皮生长因子受体激活突变阳性非小细胞肺癌中的疗效：外显子19缺失与外显子21突变有何不同？

Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation

著录项

相似文献

相关主题

期刊订阅